POP-OUT | CLOSE

An Information Portal to 105097 Biological Macromolecular Structures

 
1-cyclopropyl-6-fluoro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
 
MFX is found in 2 entries
MFX
  •   Chemical Component Summary   Hide
    Name 1-cyclopropyl-6-fluoro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
    Identifiers 7-[(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-quinoline-3-carboxylic acid
    Synonyms moxifloxacin
    Formula C21 H24 F N3 O4
    Molecular Weight 401.43 g/mol
    Type non-polymer
    Isomeric SMILES
    InChI
    InChI key FABPRXSRWADJSP-MEDUHNTESA-N
     
  •   Drug Info: DrugBank Hide
    DrugBank ID DB00218   (Stereoisomeric match)
    Name Moxifloxacin
    Groups
    • approved
    • investigational
    Description Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
    Synonyms
    • 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4as,7as)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid
    • Moxifloxacin
    Salts Moxifloxacin Hydrochloride
    Brand names
    • Avelox
    • MOXEZA
    • Vigamox
    Affected organism Enteric bacteria and other eubacteria
    Indication For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
    Pharmacology Moxifloxacin is a quinolone/fluoroquinolone antibiotic. Moxifloxacin can be used to treat infections caused by the following bacteria: Aerobic Gram-positive microorganisms: <i>Corynebacterium</i> species, <i>Micrococcus luteus</i>, <i>Staphylococcus aureus</i>, <i>Staphylococcus epidermidis</i>, <i>Staphylococcus haemolyticus</i>, <i>Staphylococcus hominis</i>, <i>Staphylococcus warneri</i>, <i>Streptococcus pneumoniae</i>, and <i>Streptococcus viridans</i> group. Aerobic Gram-negative microorganisms: <i>Acinetobacter lwoffii</i>, <i>Haemophilus influenzae</i>, and <i>Haemophilus parainfluenzae</i>. Other microorganisms: <i>Chlamydia trachomatis</i>.<br/>Moxifloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. Notably the drug has 100 times higher affinity for bacterial DNA gyrase than for mammalian. Moxifloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria.
    Mechanism of action The bactericidal action of moxifloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division.
    Route of administration
    • Intravenous
    • Ophthalmic
    • Oral
    Categories Quinolones
    ATC-Code
    • S01AE07
    • J01MA14
    AHFS-Code
    • 08:12.18
    • 52:04.04
    CAS number 354812-41-2
    Targets
    Name Sequence search Pharmacological action Actions
    DNA gyrase subunit A   Search  yes inhibitor
    DNA topoisomerase 4 subunit A   Search  yes inhibitor
    DNA topoisomerase 2-alpha   Search  unknown inhibitor
    DNA topoisomerase 2-alpha   Search  unknown inhibitor
     
Ligand Image